Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
News Nov 12, 2013
Dr. Afshin Safavi, Founder and Chief Scientific Officer at BioAgilytix Labs, said: “As a trusted partner to six of the top ten global pharmaceutical and biotech companies, it is vital that we broaden our technology offering and continue to deliver the highest quality bioanalysis possible. In the hands of our highly experienced scientists, the Gyros platform will allow BioAgilytix to continue to provide the quality data our customers have grown to expect, while also meeting growing capacity demands. Moreover, the nanoliter scale of the platform enables us to generate such data from small volumes of precious sample, maximizing the number of assays that can be performed.”
“Major biopharmaceutical companies are increasingly desiring that immunoassay testing be developed and completed using Gyrolab xP workstations due to its high precision, low sample volumes, and ease with which assays can be transferred,” commented Dan Calvo, CEO at Gyros. “We are delighted that BioAgilytix has adopted the Gyros platform and are confident it will enable them to continue to provide their customers with high quality bioanalysis.”
Gyros platform comprises Gyrolab workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE